• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

    13.77 -0.22 (-1.61%)
    Streaming Delayed Price Updated: 1:44 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 96,091
    Open 14.00
    Bid (Size) 13.74 (300)
    Ask (Size) 13.79 (400)
    Prev. Close 13.99
    Today's Range 13.54 - 14.18
    52wk Range 11.95 - 73.06
    Shares Outstanding 54,462,518
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
    Via MarketMinute
    Top movers in Friday's after hours session ↗
    Via Chartmill

    Performance

    YTD
    -80.9%
    -80.9%
    1 Month
    -6.9%
    -6.9%
    3 Month
    -80.9%
    -80.9%
    6 Month
    -70.7%
    -70.7%
    1 Year
    -46.0%
    -46.0%

    More News

    Read More
    News headline image
    The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
    Via MarketMinute
    Topics ETFs Intellectual Property
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
    Via Benzinga
    News headline image
    Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗
    Via Benzinga
    News headline image
    Looking Into Avidity Biosciences Inc's Recent Short Interest ↗
    Via Benzinga
    News headline image
    Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗
    Via The Motley Fool
    News headline image
    Unusual volume stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    $1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗
    Via Benzinga
    News headline image
    RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Via Benzinga
    News headline image
    This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Atrium Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Atrium Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Atrium Therapeutics, Inc. - Common Stock trade on?
    Atrium Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Atrium Therapeutics, Inc. - Common Stock?
    The ticker symbol for Atrium Therapeutics, Inc. - Common Stock is RNA on the Nasdaq Stock Market
    What is the current price of Atrium Therapeutics, Inc. - Common Stock?
    The current price of Atrium Therapeutics, Inc. - Common Stock is 13.77
    When was Atrium Therapeutics, Inc. - Common Stock last traded?
    The last trade of Atrium Therapeutics, Inc. - Common Stock was at 04/08/26 01:44 PM ET
    What is the market capitalization of Atrium Therapeutics, Inc. - Common Stock?
    The market capitalization of Atrium Therapeutics, Inc. - Common Stock is 749.68M
    How many shares of Atrium Therapeutics, Inc. - Common Stock are outstanding?
    Atrium Therapeutics, Inc. - Common Stock has 750M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.